B01 Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting Semaphorin4D, and rational combination therapies. Elizabeth Evans, Vaccinex, Rochester, NY, United States.

B02 Targeting CSK kinase activity to enhance anti-tumor immunity. Susan Wee, Bristol-Myers Squibb, Princeton, NJ, United States.

B03 RNAi-mediated α-catenin inhibition sensitizes non-inflamed tumors to immune checkpoint blockade. Shanthi Ganesh, Dicerna Pharmaceuticals, Inc, Cambridge, MA, United States.

B04 CDK4/6 inhibition triggers an anti-tumor immune response. Molly DeCristo, Brigham & Women's Hospital, Boston, MA, United States.

B05 Adenosine generation limits the ability of radiation therapy to induce anti-tumor immunity by abrogating recruitment and activation of CD103+ DCs. Erik Wennerberg, Weill Cornell Medicine, New York, NY, United States.

B06 Enhancement of checkpoint inhibitor efficacy by combination treatment with a novel COX2/sEH Dual Inhibitor. Maike Zimmermann, UC Davis School of Medicine, Sacramento, CA, United States.

B07 Immunostimulatory Gene Therapy Enhances PD-1 Blockade Antibody Therapy in Experimental Lung Cancer. Angelica Loskog, Uppsala University, Uppsala, Sweden.

B08 Pharmacological reactivation of MYC-dependent apoptosis induces immune activation in breast cancer. Heidi Haikala, Translational cancer biology research program, University of Helsinki, Helsinki, Finland.

B09 TLR1/2 ligand promotes Fc gamma RIV mediated depletion of tumor-infiltrating treg by anti-CTLA-4 antibody and its anti-tumor efficacy. Naveen Sharma, The UT MD Anderson Cancer Center, Houston, TX, United States.


B11 Low-dose HMGN1 synergistically enhances anti-tumor immunity in CD4 depleting antibody-treated mice. Chang-Yu Chen, Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

B12 Temozolomide combined with blockade of cytoprotective ion transport proteins NKCC1 or NHE1 reduces glioma growth and prolongs animal survival. Xiudong Guan, UNIVERSITY OF PITTSBURGH, Pittsburgh, PA, United States.
B13 New drug repositioning of low-dose pegylated IFN-alpha in combination with BH3 interacting domain death agonist gene and radiation therapy as a cancer treatment regimen. Takaya Tsuno, Kochi Medical Sciences Center, Kochi, Japan.

B14 TCR transgenic T cells improve the anticancer potential of oncolytic Vesicular stomatitis virus as cell carriers and as synergistic therapeutics. Michael Melzer, Klinikum rechts der Isar, Munich, Germany.


B16 Preclinical evaluation of niraparib in combination with anti-PD1/anti-PDL1 in mouse-derived syngeneic transplant models. Sarah Wang, TESARO Inc., Waltham, MA, United States.

B17 FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies. Beata Pyrzynska, Medical University of Warsaw, Warsaw, Poland.

B18 Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies. Denise Faustman, Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States.

B19 Modulation of cytotoxic effects of vemurafenib by chloroquine in malignant melanoma cells G-361: role of dermcidin. Jose Belizario, Department of Pharmacology, Institute of Biomedical Sciences, Univeristy of Sao Paulo, Sao Paulo, Brazil.


B21 Loss of transcriptional fidelity in a subset of cancers confers immunotherapy resistance. Kakajan Komurov, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

B22 Lymphocytes inhibits the tumor metastasis in 4D cellular lung model by reducing the number of live CTCs in circulation. Dhruva Mishra, Houston Methodist Research Institute, Houston, TX, United States.

B23 Genetic mechanisms of immune evasion in colorectal cancer. Marios Giannakis, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

B24 Digital signatures of T cell dysfunction predict immunotherapy response. Peng Jiang, Dana Farber Cancer Institute, Boston, MA, United States.


B26 Genomic analysis of the virus-induced tumor microenvironment in six cancer types. Frederick Varn, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.

B27 B-cell lymphoma response to anti-CD20 antibodies based therapies is tightly modulated by FOXO1 mediated MS4A1 gene transcription. Abdessamad Zerrouqi, Medical University of Warsaw, Warsaw, Poland.


B30 Digital multiplex immunofluorescence analysis identifies immune profiles in the tumor stroma associated with clinical outcome. Artur Mezheyeuski, Uppsala University, Uppsala, Sweden.

B31 Autofluorescence imaging of macrophage metabolism during tumor-mediated 3D migration. Tiffany Heaster, University of Wisconsin-Madison, Madison, WI, United States.

B32 Microfluidics to study solid tumor-NK cell interactions: from migration and cytotoxicity to therapeutic antibodies. Jose Ayuso, University of Wisconsin-Madison, Madison, WI, United States.


B34 The emerging role of tissue-resident memory T (Trm) cells in antitumor immunity and cancer immunotherapy. Fathia MAMI-CHOUAIB, INSERM U1186, Gustave Roussy Cancer Center, Villejuif, France.

B35 Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis. Jennifer Guerriero, Dana-Farber Cancer Insitute, Boston, MA, United States.

B36 Preventing the recurrence of breast cancer at the metastatic niche using resolution-phase macrophages. Dalit Barkan, University of Haifa, Haifa, Israel.

B37 Clinical relevance of tumor-infiltrating immune cells in neuroblastoma. Doriana Fruci, Bambino Gesù Children Hospital, Rome, Italy.


B39 Understanding the association of gut microbiota and tumor microenvironment in gastric and esophageal cancer. Prashant Thakkar, Weill Cornell Medicine, New York, NY, United States.

B41 Neutrophils modulate T-cell recruitment and promote hepatic metastases in lung cancer. Roni Rayes, McGill University Health Center, Montreal, QC, Canada.

B42 MDSCs accumulation within metastatic liver is modulated by CXCR4/CXCL12 axis after HSCs interaction with C26 in the ICAM-1 regulated inflammatory milieu. Aitor Benedicto, University of the Basque Country, Leioa (Bilbao), Bizkaia, Spain.


B44 Regulation of macrophage activation by vascular niche in glioblastoma. Yi Fan, University of Pennsylvania, Philadelphia, PA, United States.

B45 Defining the interaction of tumor promoting galectin-9 with macrophages via the CD206 receptor. Elizabeth Ann Enninga, Mayo Clinic, Rochester, MN, United States.

B46 Roles for LKB1 at the immune synapse during B cell activation and anti-tumor responses. Laura Jimenez, University of California Los Angeles, Los Angeles, CA, United States.
B47 Potent anti-tumor immunity is induced by activation of the STING pathway within the tumor microenvironment using synthetic cyclic dinucleotides. LETICIA CORRALES, Aduro Biotech, Berkeley, CA, United States.


B49 Proteomic profiling of breast cancer-derived exosomes reveals differential expression of key metastatic factors associated with macrophage polarization. Hyewon Chung, Department of Microbiology and Immunology, Institute of Endemic Disease, College of Medicine, Seoul, Korea, Republic Of.

B50 The tumor immune microenvironment following acute liver injury in mice with genetic predisposition for cholangiocarcinoma. Nathania Figueroa, University of Rochester Medical Center, Rochester, NY, United States.

B51 Quantitative multiplex immunofluorescence reveals that chemoradiation therapy favorably modulates the tumor immune microenvironment of pancreatic cancer. Thomas Enzler, Columbia University Medical Center, New York, NY, United States.

B52 Effects of tissue site and antigenicity on KPC-derived pancreatic tumor growth and response to combination immunotherapy. Casey Ager, MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, United States.

B53 Intra-tracheal delivery of low dose bacterial lipopolysaccharides protects against tumor formation in the KP lung adenocarcinoma model. Ganapathy Sriram, Massachusetts Institute of Technology, Cambridge, MA, United States.

B54 Dissecting immune cell heterogeneity in human cancer by single-cell RNA-sequencing. Ido Yofe, Weizmann Institute of Science, Rehovot, Israel.

B55 Knockdown of Na/H exchanger isoform 1 (NHE1) reduces glioma-associated microglia/macrophage infiltration and activation, suppresses T-cell activation and PD-1/PD-L1 expression in mouse glioma model. Nabiul Hasan, University of Pittsburgh, Pittsburgh, PA, United States.

B56 CXCR2 blockade reduces granulocytic myeloid cell compensation in response to macrophage targeted therapy and further enhances the efficacy of chemotherapy in pancreatic ductal adenocarcinoma. Booyeon Han, University of Rochester, Rochester, NY, United States.


B58 The role of EphA2 receptor tyrosine kinase in anti-tumor immunity mediated through programmed death ligand 2 (PD-L2) in non-small cell lung cancer (NSCLC). Eileen Shiuan, Vanderbilt University Medical Center, Nashville, TN, United States.

B59 Survival benefit of Tumor Infiltrating Lymphocytes in Ovarian Cancer is dependent on Major Histocompatibility Complex class I expression after primary surgery and not after neoadjuvant chemotherapy. Kim Brunekreeft, University Medical Center Groningen, Groningen, Netherlands.

B60 The interplay between CLL cells and the dendritic cells in their bone marrow microenvironment. Avital Barak, Weizmann Institute of Science, Rehovot, Israel.
B61 Heavy and Light Chain Reconstruction of Tumor-infiltrating B Cell Receptors from RNA-seq data. Xihao Sherlock Hu, Dana Farber Cancer Institute, Boston, MA, United States.

B62 Immune gene expression profiling identifies predictors of relapse in childhood acute myeloid leukemia. Sergio Rutella, Nottingham Trent University, Nottingham, United Kingdom.

B63 Bitter sweet symphony: How tumor-associated glycan structures orchestrate immune evasion. Lenneke Cornelissen, VU University medical center, Amsterdam, Netherlands.

B64 Characterizing the tumor immune microenvironment of metastatic and non-metastatic renal clear cell carcinomas and colorectal carcinomas using computational methods. Yasmin Kamal, Geisel School of Medicine, Lebanon, NH, United States.

B65 Characterizing the immune cellular components of the tumor microenvironment to identify suitable syngeneic breast cancer models for pre-clinical investigations using immunomodulators. Jessica Castrillon, Dana-Farber Cancer Institute, MA, United States.

B66 Targeted activation of innate immune adaptors MAVS and STING promotes anti-tumor responses in colorectal cancer models. Li-Chung Tsao, Duke University, Durham, NC, United States.

B67 Regulation of a novel cell surface protein in macrophage activity in tumor microenvironment. Rashmi Ray, Institute of Life Sciences, Bhubaneswar, Odisha, India.

B68 Targeted inhibition of Tgfαr2 reduces IL-6 production from cancer-associated fibroblasts, suppresses Stat3 activation in pancreatic cancer cells and reverses immunosuppression. Huocong Huang, University of Texas Southwestern Medical Center, Dallas, TX, United States.

B69 A new E3 ubiquitin ligase regulates the immune response in colon cancer. Camille Spinner, Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.

B70 Oncogenic Kras controls T cells in pancreatic adenocarcinoma. Elena Rodriges Blanko, MD Anderson Cancer Center, Houston, TX, United States.

B71 CXCR3 is expressed by infiltrating T-cells and dendritic cells and is required for tumor development in a mouse model of plexiform neurofibroma. Jonathan Fletcher, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

B72 Secretory autophagy in tumor-associated fibroblasts alter effector function of natural killer cells against HNSCC. Jonathan Enders, Kansas University Medical Center, Kansas City, KS, United States.

B73 Pleiotrophin drives a pro-malignant macrophage phenotype in preclinical models of breast cancer. Noah Sorrelle, University of Texas Southwestern Medical Center, Dallas, TX, United States.

B74 High-dimensional profiling of immune checkpoints and their ligands in a glioblastoma and pancreas cancer mouse model. Yvette van Kooyk, VU medical centre, Amsterdam, Netherlands.

B75 Loss of cross-presentation by tissue resident DC1 in lung adenocarcinomas is an early event that correlates to exhaustion of endogenous anti-tumor CD8+ T cell responses. Federica Benvenuti, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.

B76 Tumor microenvironment immunosuppression: “Role of neglected molecules iron and HLA-G”. Robert Elliott, Sallie Astor Burdine Breast Foundation, Baton Rouge, LA, United States.
B77 Low density neutrophils (LDN) in circulating blood of postoperative patients may participate in the development of distant recurrence through the production of neutrophil extracellular traps (NETs). JOJI KITAYAMA, Department of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.

B78 Irreversible electroporation (IRE) acts as an "in situ vaccine" and induces anti-tumor immune responses in pancreatic cancer. Jayanth Narayanan, University of California San Diego, La Jolla, CA, United States.

B79 Identification and analysis of tumor reactive CTLs in ovarian and cervical cancer tissues for developing a personalized immunotherapy. Kazuto Nosaka, National Cancer Center, Kashiwa City, Japan.

B80 Mass Spectrometric Characterization of Peptides Associated with Molecules of the Major Histocompatibility Complex. Michael Ford, MS Bioworks LLC, Ann Arbor, MI, United States.


B82 Identification of tumor neoantigens for combination therapy in murine tumor models. Karin Lee, National Cancer Institute, Bethesda, MD, United States.

B83 Intratumoral T cell receptor α repertoire as a biomarker in Head and Neck Squamous Cell Carcinoma. Lara McGrath, AstraZeneca, Waltham, MA, United States.


B85 Identification of breast cancer neoantigens exposed by radiation therapy. Claire Lhuillier, Weill Cornell Medical College, NY, United States.

B86 Circulating cytokines, chemokines, and small molecules follow distinct expression patterns in acute myeloid leukemia. Mirazul Islam, Dana-Farber Cancer Institute, Boston, MA, United States.

B87 Exosomal histones as potential regulators of melanoma metastasis. Roman Alpatov, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

B88 Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27 dependent pathway. Ashvin Jaiswal, MD Anderson Cancer Center, Houston, TX, United States.